secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001558370-25-000151
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte reports preliminary FY2024 core revenue $32.2M-$32.4M, up 8-9% YoY
--------------------------------------------------------------------------

- Q4 2024 core revenue expected $8.3M–$8.5M vs $7.2M in Q4 2023.
- Full-year core revenue $32.2M–$32.4M, up 8–9% from $29.8M in FY2023.
- Cash and investments ~$190M at Dec 31, 2024, above updated guidance of $185M.
- Added six SPL customers in 2024; supported launch of first FDA-approved non-viral gene-edited cell therapy.
- Audited FY2024 results expected in March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837025000151/0001558370-25-000151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837025000151/mxct-20250113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer